Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed.

Septerna takes a different approach to the disease with SEP-786, a small molecule that targets and activates the parathyroid hormone 1 receptor (PTH1R), sparking it to produce more of the key hormone.

Septerna continues to advance multiple lead compounds with distinct chemical structures unrelated to its first-generation oral small molecule, SEP-786, each with favorable pharmacokinetics (PK ...

Septerna, Inc. is a clinical-stage biotechnology company focusing on the discovery and development of oral small molecule drugs targeting G protein-coupled receptors (GPCRs) for various ...

A couple of analysts initiated coverage on Septerna, Inc. (NASDAQ:SEPN), which debuted on NASDAQ last month. Cantor analyst Josh Schimmer initiated coverage at an Overweight rating with a price ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments.

Septerna’s current cash pile includes $47.6 million it received from Vertex in return for a GPCR program. The deal includes a potential payment tied to a research milestone.

TD Cowen initiated coverage of Septerna (SEPN) with a Buy rating and no price target The company is applying its Native Complex platform to build a pipeline of oral small molecule G protein ...

The Septerna technology platform is called Native Complex. In addition to isolating GPCRs, the technology screens libraries of molecules to find the ones that can bind to the receptors.

--Septerna, Inc., a biotechnology company pioneering a new era of G protein-coupled receptor drug discovery, today highlighted key business updates and upcoming milestones and reported financial ...